

ESMO 2023 Industry Satellite Symposium

Expanding Horizons

# Clinical and Patient Perspectives on CDK4/6 Inhibitors in HR+/HER2- Early Breast Cancer



Sunday, 22 October, 2023



13:00-14:30 CEST



Valencia Auditorium,  
Hall 10, IFEMA MADRID,  
Madrid, Spain

## Faculty



**Michael Gnant, MD, FACS, FEBS  
Chair**

*Professor, Surgery  
Comprehensive Cancer Center  
Medical University of Vienna  
Vienna, Austria*



**Martine Piccart, MD**

*Professor, Medical Oncology  
Institut Jules Bordet  
Brussels, Belgium*



**Renate Haidinger**

*Patient Advocate  
Neubiberg, Germany*

## Agenda

- Unmet Need in HR+/HER2- Early Breast Cancer
- Efficacy of CDK4/6i in HR+/HER2- Early Breast Cancer
- Safety and QoL with CDK4/6i in HR+/HER2- Early Breast Cancer
- QoL and Treatment Adherence in Early Breast Cancer: The Patient Perspective
- Q&A

This scientific program and/or material was developed for use outside of the US, intended for non-US HCPs licensed to prescribe medicine, and is to be used in accordance with local laws and regulations. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country. This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.



Novartis Pharma AG

CH-4002 Basel Switzerland

© 2023 Novartis

294004 | 07/23 | P3 Id: ES2308167842